National Cancer Institute: Utilization of Innovative Technologies in Cancer Research Grants

Opportunity ID: 44376

General Information

Document Type: Grants Notice
Funding Opportunity Number: RFA-CA-09-007
Funding Opportunity Title: Application and Use of Transformative Emerging Technologies in Cancer Research (R33)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Education
Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.392 — Cancer Construction
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Dec 15, 2008
Last Updated Date:
Original Closing Date for Applications: Sep 30, 2009
Current Closing Date for Applications: Sep 30, 2009
Archive Date: Oct 31, 2009
Estimated Total Program Funding: $1,000,000
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants: For profit organizations other than small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
Small businesses
Public and State controlled institutions of higher education
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
State governments
Additional Information on Eligibility: Other Eligible Applicants include the following:
Eligible Agencies of the Federal Government; Non-domestic (non-U.S.) Entities (Foreign Organizations); U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description: Purpose. This Funding Opportunity Announcement (FOA) issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), solicits grant applications proposing exceptionally innovative, high risk, original and/or unconventional research projects focused on evaluating the performance of emerging, potentially transformative molecular and cellular analysis technologies within the context of an appropriate cancer-relevant biological system. The emphasis of this FOA is on the application of emerging molecular and cellular analysis tools with the potential to (i) create new or challenge existing scientific and technological paradigms and/or (ii) overcome technological barriers in important areas of cancer research. Projects must clearly demonstrate potential to produce a major impact in a broad area of biomedical or cancer-relevant research through application to a relevant biological system. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program. Several IMAT FOAs of identical or closely related scientific scope using various funding mechanisms are available. To facilitate selection, a separate Notice in the NIH Guide for Grants and Contracts provides brief cross-comparison and links to all the IMAT FOAs. See NOT-CA-09-007.
Link to Additional Information: http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-09-007.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV

Email:FBOWebmaster@OD.NIH.GOV

Version History

Version Modification Description Updated Date

Related Documents

Packages

Agency Contact Information: NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV

Email: FBOWebmaster@OD.NIH.GOV

Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
ADOBE-FORMS-A Adobe-Forms-A PKG00009695 Jan 23, 2009 Sep 30, 2009 View

Package 1

Mandatory forms

44376 RR_SF424-1.1.pdf

44376 RR_KeyPersonExpanded-1.1.pdf

44376 RR_OtherProjectInfo-1.1.pdf

44376 RR_PerformanceSite-1.1.pdf

44376 RR_Budget-1.1.pdf

44376 PHS398_CoverPageSupplement-1.1.pdf

44376 PHS398_ResearchPlan-1.1.pdf

44376 PHS398_Checklist-1.1.pdf

Optional forms

44376 PHS398_CoverLetter-1.1.pdf

44376 RR_SubawardBudget-1.2.pdf


Comments

Leave a Reply

Your email address will not be published. Required fields are marked *